https://doi.org/10.4081/hmr.v1i7.629

The role of monoclonal antibodies in the therapeutic strategy of chronic lymphocytic leukemia

Vol. 1 No. 7: Chronic Lymphocytic Leukemia: Achievements and Controversies
Published: June 16, 2009
Abstract Views: 172
PDF: 285
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Agostino Cortelezzi
support@pagepress.org
Monoclonal antibodies (MoAb) have led to a profound shift in the therapeutic scenario of CLL. Alemtuzumab and rituximab are the most active MoAbs to date, and their single-agent activity has been established both in previously untreated and in relapsed patients with CLL. MoAbs act through unique mechanisms distinct from conventional cytotoxic chemotherapy: engagement of restricted cell-surface antigens, activation of intracellular pro-apoptotic signaling pathways, and activation of effector functions, including components of the complement system and antibody-dependent cellular cytotoxicity through the activation of natural killer cells and macrophages through their IgG fragment C receptors.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Cortelezzi, A. (2009). The role of monoclonal antibodies in the therapeutic strategy of chronic lymphocytic leukemia. Hematology Meeting Reports (formerly Haematologica Reports), 1(7). https://doi.org/10.4081/hmr.v1i7.629
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).